Jennifer Sy - 17 Feb 2026 Form 4 Insider Report for AEON Biopharma, Inc. (AEON)

Signature
/s/ Alexander Wilson, as Attorney-in-Fact, for Jennifer Sy
Issuer symbol
AEON
Transactions as of
17 Feb 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 18:06:25 UTC
Previous filing
23 May 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sy Jennifer PRINCIPAL ACCOUNTING OFFICER C/O AEON BIOPHARMA, INC., 5 PARK PLAZA, SUITE 1750, IRVINE /s/ Alexander Wilson, as Attorney-in-Fact, for Jennifer Sy 05 Mar 2026 0002023998

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AEON Class A Common Stock Award +575,000 +229084% $0.000000* 575,251 17 Feb 2026 Direct F1
transaction AEON Class A Common Stock Award +925,925 +161% $0.000000* 1,501,176 04 Mar 2026 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.
F2 Represents outstanding cash-settled restricted stock units granted on May 21, 2025 (the "Grant Date") that were modified on March 4, 2026 to be settled in stock instead of cash upon vesting. The restricted stock units continue to vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. The restricted stock units were originally reported in Table II on a Form 4 filed on May 23, 2025.